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Background. Acute myocardial infarction of the right venricle (AMI-RV) is a separate
subgroup within the scope of inferoposterior infarction of the left ventricle. It still rep-
resents the population of patients at high risk due to numerous, often hardly predict-
able complications and high mortality rate. Methods. In fifteen-year period
(1987−2001) 3 765 patients with the acute myocardial infarction (AMI) of different lo-
calizations of both sexes – 2  283 males and 1  482 females of the average age
61.4 ± 4.6 years were treated in our institution. Anterior myocardial infarction was di-
agnosed in 2 146 (56.9%) patients, inferior in 1 619 (43.1%) patients, out of whom
right ventricular infarction (RVI) was confirmed in 384 (23.7%). Thrombolytic therapy
was administered in 163 (42.4%) patients with RVI, and in 53 (41.7%) of these pa-
tients balloon dilatation was performed with coronary stent implantation in 24
(45.2%). Results. Favorable clinical effect of the combined thrombolytic therapy and
percutaneous transluminal coronary angioplasty (PTCA) was achieved in 51 (96.1%),
and in only 2 (3.9%) of patients the expected effect wasn't achieved. Myocardial revas-
cularization was accomplished in 6 (3.6%) and 1 patient died. In 3 (3.4%) patients
primary balloon dilatation with the implantation of intracoronary stent was performed
within 6 hours from the onset of anginal pain. In the other group of 221 (57.5%) pa-
tients with RVI who did not receive thrombolytic therapy, or it had no effect, 26
(11.7%) patients died, which indicated the validity and the efficacy of this treatment
(p<0,01). In the whole group of patients with myocardial infarction of the right ventri-
cle 31 (8.1%) died; in the group that received thrombolytic therapy and PTCA 5
(3.1%) died, while in the group treated in a conservative way 26 (11.7%) died. Con-
clusion. Combined therapy was successful in the treatment of patients with RVI and
should be administered whenever possible, since it was the best prevention of life-
threatening complications and the decrease in the mortality of those patients.
K e y  w o r d s : myocardial infarction; ventricular dysfunction, right;
fibrinolytic agents; balloon dilatation; angioplasty,
transluminal, percutaneous coronary; stents; combined
modality therapy; treatment outcome.
Introduction
Current treatment of AIM comprises volume compen-
sation due to the reduced minute volume, combined throm-
bolytic, antiaggregation and anticoagulant therapy, together
with primary or delayed (elective) percutaneous translumi-
nal coronary angioplasty (PTCA) and intracoronary stent
implantation, if necessary (1−6).
According to many previously published studies the
incidence of AMI-RV ranged from 13 to 56%, depending
on population, clinical, ECG, hemodynamic or patho-
anatomic criteria. Mortality rate ranged from 20 to 50%
(7−12). The results of the GUSTO IIb study showed that
PTCA alone led to 45% of new restenoses during the four
month follow-up period and therefore the effect of such
therapy was practically annullated, although in the first actСтрана 588 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Број 6
it resulted with the complete potency of the infarcted artery
(13−15). Owing to this, new studies − CADILLAC before
all, as well as the others, suggested the administration of di-
rect inhibitors of the platelet glycoprotein IIb/IIIa (abcixi-
mab) together with intracoronary low-molecular heparin.
This modified therapy proved itself much more effective not
only in infarction size and mortality rate reduction, but also
in the lowered incidence of the complications such as myo-
cardial reinfarction, restenosis, cerebrovascular accidents,
during the hospital treatment, but also during one-year follow-
up period after patients were discharged from the hospital
(16−17). The application of any of these individual treatment
methods or of their combination was aimed for primary pre-
servetion of the myocardium, as well as for the management
of reocclusion and restenosis (18−19). Widely accepted
thrombolytic therapy together with more and more frequent
PTCA generally used in the treatment of myocardial infarc-
tion and particularly in patients with AMI-RV, started a new
era of interventional cardiology, as well as of the active ap-
proach in the treatment of these patients (20−24).
The aim of this study was to present our results with
combined fibrinolytic therapy achived in the treatment of
patients with AMI-RV, using accelerated tissue-type plas-
minogen activator protocol and primary or delayed PTCA
together with intracoronary stent implantation, if necessary.
Obtained results within one month intrahospital period were
correlated with the clinical, ECG, echocardiographic and
scintigraphic (SPECT) findings when necessary, radionu-
clide ventriculography (RV) and coronarography, or
autopsy findings in patients who died.
Methods
Within the fifteen-year period (1987-2001), 3 765 pa-
tients of both sexes, 2  283 (60.6%) males and 1  482
(39.4%) females aged 60.1± 4.6 years in average underwent
treatment of the acute myocardial infarction (AMI) of vari-
ous localizations at the Clinic of Emergency Internal Medi-
cine, Military Medical Academy (MMA). Infarction of an-
terior localization occurred in 2  146 (56.9%) and infero-
posterior one in 1 619 (43.1%) of patients, which was con-
firmed in 384 (23.7%) cases of AMI-RV. Thrombolytic
therapy was administered in the first 6−12 hours from the
onset of anginous pain, and primary or delayed PTCA 6
hours up to 21 days after the infarction being confirmed
clinically. They were performed by ECG, enzyme tests,
echocardiography or radionucleide imaging of the myocar-
dium, if necessary, and by autopsy in fatal cases. Selective
coronarography was performed in all patients on thrombo-
lytic therapy, aiming to evalute the obtained effect and to
come to decision concerning further treatment. All results
were analysed using χ
2 test in statistical analysis. During the
last three years the modified treatment protocol was used
introducing platelet glycoprotein IIb/IIIa inhibitors (abcixi-
mab) together with low-molecular heparin − enoxaparin in
the dosis of 20 mg intracoronary.
Results
There were 384 patients in the group with AMI-RV,
229 (59.6%) males and 155 (40.4%) females and the aver-
age age of the whole group was 60.2 ± 5.8 years. Fibrino-
lytic therapy was administered to 163 (42.4%) patients and
satisfactory reperfusion according to clinical, ECG and en-
zime criteria was achieved in 111 (68.1%) patients, but
without the expected effect in 52 (31.9%) of patients. In the
thrombolytic therapy group in 53 (41.7%) patients delayed
or elective PTCA was performed in the later period and
complete dilatation only by balloon was achieved in 27
(50.9%) patients. Partial effect of dilatation with remained
lower degree stenosis was successfully managed by intra-
coronary stent implantation in 24 (45.2%) patients. Myo-
cardial surgical revascularisation was done in 2 (3.9%) pa-
tients.
Primary percutaneous transluminal coronary angio-
plasty (PPTCA) was performed in 3 (3.9%) patients (2 fe-
males and 1 male) within the first 6 hours from the onset of
anginous pain due to threatening cardiogenic shock and
marked conduction disorders (AV block I
0−III
0). Complete
effect of thrombolytic therapy combined with PTCA with
coronary stenting was accomplished in 51 (96.1%) of pa-
tients with no fatal outcome and no serious clinical compli-
cations in the later course. Myocardial revascularization
was found in 6 (3.6%) patients, while in the whole group
receiving thrombolytic therapy together with primary or
delayed PTCA and intracoronary stent 5 (3.1%) patients
died − 3 in cardiogenic schock, 1 after a bypass surgery and
1 due to myocardial rupture. Coronary angiography showed
pathologic changes in one blood vessel in 28 (22%), two in
36 (28.4%), and three in 47 (37%) patients, while 16
(11.5%) of them had tortuous changes of coronary arteries
without significant stenosis.
In the group of 221 patients with AMI-RV who did not
receive thrombolytic therapy or it was ineffective, 26
(11.7%) of them died. In the group receiving combined fi-
brinolytic therapy and PTCA 5 (3.1%) patients died (χ
2 test-
9.56; p<0.0l), and in the whole group of 384 patients with
the established AMI-RV 31 (8.1%) patient died, which un-
doubtedly confirmed the efficiency and justification of fi-
brinolytic therapy administration combined with PTCA in
accordance with the modified protocol.
Discussion
Owing to the size of necrosis affecting the lower wall
of both ventricles, distal half of interventricular septum, free
wall of the right ventricle, papillary muscles together with
the valvular apparatus, as well as cardiac conduction sys-
tem, the infarction of the left and the right ventricle was in
fact combined in patients with AMI-RV. It made their
prognosis uncertain and mortality rate was still very high
(25−27). The underlying physiopathologic substrate was
stenosis or occlusion of proximally one third of the rightБрој 6 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Страна 589
coronary artery (RCA), less frequently of the circumflex
artery which was always predominant so that both sinus and
AV node perfusions could have been compromised. This
was clinically manifested as sinus bradycardia, hypotension,
high degree AV block (II
0−III
0), or as the rapid develop-
ment of cardiogenic shock (28−30). Current therapy rec-
ommends thrombolytic agents together with PTCA as an
obligation aiming to open infarcted arteries as soon as pos-
sible and to definitely manage occlusion or stenosis
(31−32).
 More than 15 years had passed before the first com-
munications on thrombolytic therapy administration in
AMI-RV resulted in satisfactory reperfusion and increased
the ejection fraction together with the less frequent AV
blocks in patients with AMI-RV, comparing those in whom
the reperfusion effect was not achieved with thrombolytic
therapy (33−34). Such observation was also confirmed by
the results in later TIMI 2 study in which thrombolytic ther-
apy administered to patients with inferior infarction con-
tributed to the reduced incidence of AMI-RV in patients
with diaphragmal infarction. In those patients satisfactory
reperfusion of the dominant RCA was achieved in compari-
son with those in whom this effect failed. This was an in-
troduction into the new treatment strategy for patients with
inferoposterior infarction in whom initial clinical signs or
ECG findings suggested possible development of AMI-RV
(35−37). The first study on successful primary angioplasty
in patients with AMI-RV in whom satisfactory hemody-
namic improvement of ejection fraction and rapid clinical
recovery were recorded (38) was published at the end of
eighties. Our experience and the obtained results in the
treatment of these patients within the fifteen-year period
were in accordance with many previous similarly designed
studies and our attitude was that in all these patients, except
for unavoidable fibrinolytic therapy, primary or most often
delayed PTCA should be performed whenever necessary
and possible, aiming to definitely manage residual stenosis.
The effect of this combined therapy was best noticeable in
the fact that in our subgroup of 27 patients with AMI-RV
treated in this way there were no fatal outcomes during the
first month of hospital treatment and that following compli-
cations were of no clinical significance. Meta-analysis of 10
world extensive randomised studies showed that primary
PTCA reduced mortality rate and non-fatal myocardial in-
farction for 7.4% in comparison with intravenous admini-
stration of fibrinolytic therapy alone with the maintaining
maximum TIMI 3 blood flow through the infarcted artery in
about 90% of patients (39). Comparing clinical, ECG and
coronarographic findings it was noticed that long and re-
peated anginous pain lasting longer than 40 minutes as the
well as development of cardiogenic shock within the first 24
hours were the indicators of the unfavourable outcome,
while the elevation of ST segment in V4 R−V5R >2 mV or
bradycardia < 50/min were ECG signs suggesting the de-
velopment of AV block III
0 or the rapid development of
cardiogenic shock. Special precaution ought to have been
taken in all these patients because these were the early signs
suggesting possible lethal outcome. These results were con-
firmed in other authors' communications and they were the
signs of poor prognosis and possible serious complications
(40−41). Sufficient konowledge of early clinical and ECG
indicators together with echocardiographic follow-up of pa-
tients enabled timely undertaken measures for elective bal-
loon dilatation, and our previous experience and the ob-
tained results completely confirmed it. The administration
of the modified protocol combined with abciximab and
enoxaparin multiply reduced the number of possible com-
plications and the mortality rate (42). However, in about
30% of patients with maintained adequate angiographic
blood flow (TIMI-3), there were clinical signs or marked,
often irreversible cardiogenic shock, because they did not
have the same blood flow on microcirculation level due to
possible massive microembolism from the dilated subepi-
cardial artery, or spontaneously developed microvascular
thrombosis associated with the spasm and edema of the sur-
rounding infarcted tissue (43, 44). Although angiography
revealed completely potent and completely dilated artery,
they died in an irreversible cardiogenic shock due to the so
called „no-reflow“ phenomenon (45, 46). Thus, in spite of
the great progress in the treatment of these patients, there
are still many unanswered questions because we do not
know why these patients still belong to the group at high
risk with the uncertain outcome.
Conclusion
Our results showed that thrombolytic therapy com-
bined with PTCA in a modified treatment protocol reduced
the incidence of complications and mortality rate in patients
with AMI-RV. This method of treatment undoubtedly re-
duced the size of necrosis and soon preserved the remained
portion of the myocardium in the blood supply area of the
infarcted artery which was shown to be the best prevention
of the life threatening complications and the best way to re-
duce the moratality rate in these patients. Interventional
cardiology also reduced the number of patients requiring
additional myocardial revascularization risks related to this
intervention and significantly lowered treatment costs.
Thrombolytic therapy combined with PTCA most often re-
sulted in rapid and complete potency of the infarcted artery,
fast clinical recovery and favourable clinical course even
after patients were discharged from the hospital. Out of
384 with AMI-RV thrombolytic therapy was administered
patients to 163 (42.4%) of them, while the delayed PTCA
together with intracoronary stent implantation was per-
formed in 53 (29.6%) of patients. Complete clinical effect
of this combined treatment was achived in 51 (96.1%) pa-
tients without the fatal outcome and serious clinical com-
plications in the further course. PPTCA and intracoronary
stent implantation were performed in 3 patients and their
later clinical course and recovery were also without com-
plications.Страна 590 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Број 6
Unfortunately, in spite of the most up-to-date methods
of treatment, mortality rate in these patients was still 4−5
times higher comparing to the ones with common infero-
posterior left ventricle infarction in which this aggressive
approach was neither necessary, nor recommendable.
The development of interventional cardiology thus in-
troduced a new strategy in the treatment of these patients
and our previous results, as well as the experience, com-
pletely confirmed this method as a very reliable one.
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Apstrakt
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SAVREMENA TERAPIJA INFARKTA MIOKARDA DESNE KOMORE
Uvod. Akutni infarkt miokarda desne komore (AIM-DK), posebna podgrupa u okvi-
ru inferoposteriornog infarkta leve komore, predstavlja veoma rizičnu bolest  zbog
brojnih, često teško predvidljivih komplikacija i visokog mortaliteta. Metode. U peri-
odu od 15 godina (1987−2001) ukupno je od akutnog infarkta miokarda (AIM) razli-
čitih lokalizacija, lečeno 3 765 bolesnika oba pola, 2 283 muškaraca i 1 482 žena,
prosečne starosti 61,4 ± 4,6 g. Infarkt prednjeg zida imalo je 2 146 (56,9%) boles-
nika, inferiorni infarkt je imalo 1 619 (43,1%) bolesnika, od kojih je kod 384 (23,7%)
bio dokazan infarkt desne komore. Trombolitičku terapiju dobilo je 163 (42,4%) sa
AIM-DK, a kod 53 (41,7%) ovih bolesnika urađena je balon dilatacija, uz implanta-
ciju intrakoronarnog stenta kod 24 (45,2%). Rezultati. Potpuni klinički efekat pri-
menom kombinovane trombolitičke terapije i perkutane translumenske koronarne
angioplastike (PTKA) postignut je kod 51 (96,1%), a očekivani efekat izostao je
samo kod 2 (3,9%) bolesnika. Revaskularizacija miokarda urađena je kod 6 (3,6%)
i jedan bolesnik je umro. Kod 3 (3,4%) bolesnika koji su primljeni na bolničko leče-
nje u prvih 6 sati od početka anginoznih bolova urađena je i direktna balon dilata-
cija sa implantacijom intrakoronarnog stenta i postignut potpuni klinički efekat. Nije
bilo ni jednog smrtnog slučaja u grupi koja je lečena kombinovanom fibrinolitičkom
terapijom i PTKA, kao ni u grupi u kojoj je primenjena primarna PTKA. U drugoj
grupi od 221 (57,5%) bolesnika sa AIM-DK koji nisu dobili trombolitičku terapiju, ili
je ona ostala bez efekta, umrlo je 26 (11,7%) što najbolje govori o uspešnosti i efi-
kasnosti ovog načina lečenja (p<0,01). U celoj grupi bolesnika sa AIM-DK umrlo je
31 (8,1%) − u grupi koja je primila trombolitičku terapiju i PTKA umrlo je 5 (3,1%),
dok je u grupi koja je lečena konzervativnom terapijom umrlo 26 (11,7%). Zaklju-
čak. Kombinovana terapija je veoma uspešna u lečenju bolesnika sa AIM-DK treba
je primeniti u svim slučajevima gde je to moguće, jer je to najbolja prevencija život-
no opasnih komplikacija uz smanjenje smrtnosti ovih bolesnika.
Kl juč ne reč i : infarkt miokarda; srce, disfunkcija desne komore;
fibrinolitici; dilatacija balonom; angioplastika,
translumenska perkutana, koronarna; stentovi;
lečenje, kombinovano, lečenje, ishod.